Sandoz Inc unveils authorised generic buprenorphine and naloxone sublingual film for the treatment of opioid dependence
20 February 2019 -

Sandoz Inc reported on Tuesday the immediate availability of the authorised generic of SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) in all four dosage strengths in the US.

The company added the buprenorphine and naloxone sublingual film (2mg/0.5mg, 4mg/1mg, 8mg/2mg and 12mg/3mg) is indicated for the treatment of opioid dependence. Buprenorphine and naloxone sublingual film should be used as part of a complete treatment plan that includes counselling and psychosocial support.

Under the company's marketing campaign, it is commercialising the US FDA-cleared prescription digital therapeutics as an adjunct to outpatient treatment to help patients with substance use disorder and opioid use disorder. It working with other partners and healthcare professionals to help address substance and opioid abuse, which requires a collaborative effort between all stakeholders, including regulatory authorities, physicians and other healthcare providers.

In conjunction, SUBOXONE is reportedly the registered trademark of Indivior UK Limited and for the period ending December 2018 (MAT: Moving Annual Target), the US sales for SUBOXONE were about USD2bn, according to IQVIA,

Sandoz Inc is a generic pharmaceuticals company and part of the Novartis division.